Research programme: anaemia therapies - Transition Therapeutics

Drug Profile

Research programme: anaemia therapies - Transition Therapeutics

Alternative Names: Anemia therapies - Transition Therapeutics; Hypoxia inducible factor prolyl hydroxylase inhibitors - Transition Therapeutics

Latest Information Update: 24 Aug 2010

Price : $50

At a glance

  • Originator Transition Therapeutics
  • Class
  • Mechanism of Action Mixed function oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 05 Jun 2008 Preclinical development is ongoing
  • 15 Mar 2006 Preclinical trials in Anaemia in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top